FLT3 and leukemia: In one preclinical study, the FLT3 inhibitor sorafenib alone was insufficient to block LSC functionality in serial transplantation experiments of leukemia into mice, but the addition of all-trans-retinoic acid (ATRA) to sorafenib abrogated transmission of leukemia to secondary recipients [146], suggesting that there are combination therapies that can effectively eradicate LSCs.